A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepato-splenic T-cell Lymphoma
Adult T-cell Leukemia/Lymphoma
Enteropathy Associated T-cell Lymphoma
NK T-cell Lymphoma

Interventions

DRUG: Brentuximab vedotin

Sponsor

Deepa Jagadeesh